Journal Club:
Clinical Cancer Research with Dr. Vivek Subbiah

Moderated by: Jacqueline Brosnan-Cashman, PhD
Clinical Cancer Research Associate Editor
Recorded: 9/10/2021

Watch the recording of the AACR Journal Club session featuring Dr. Vivek Subbiah, discussing his article recently published in Clinical Cancer Research, "Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial." In this paper, Dr. Subbiah and colleagues describe safety and efficacy results of the LIBRETTO-001 Phase I/II trial in patients with RET fusion-positive NSCLCs with intracranial metastases. Brain metastases are a major cause of morbidity and mortality in patients with RET fusion-positive non-small cell lung cancers. Selpercatinib was well tolerated in this patient population, achieving a high intracranial response rate, as well as prolonged intracranial duration of response and intracranial progression-free survival. Based on these data, further clinical assessment of selpercatinib is underway.

Stay tuned for the Q&A session at the end of the recording.

About the Featured Speaker:

Vivek Subbiah, MD is an associate professor in the Investigational Cancer Therapeutics department (a Phase 1 program). He is the Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine division, at The University of Texas MD Anderson Cancer Center.